Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, have announced that an independent data review of the Phase 3 Mosaico study of Janssen’s investigational HIV vaccine regimen was not effective in preventing HIV infection among the study participants. The study will be discontinued and further analysis of the data will be conducted. They revealed no safety issues with the vaccine regimen were identified during the trial. The consortium of global partners
The Joint United Nations Programme on HIV/AIDS (UNAIDS) has announced that it is strongly encouraged by new study results showing that the antiretroviral medicine cabotegravir, which is administered by injection every two months, prevents HIV among women. The study shows that the long-acting injections among women in sub-Saharan Africa were 89% more efficient in preventing HIV compared to daily tablets of pre-exposure prophylaxis (PrEP). “These results are hugely significant. UNAIDS has long been calling for additional, acceptable and effective HIV prevention options